probucol has been researched along with Recrudescence in 19 studies
Probucol: A drug used to lower LDL and HDL cholesterol yet has little effect on serum-triglyceride or VLDL cholesterol. (From Martindale, The Extra Pharmacopoeia, 30th ed, p993).
probucol : A dithioketal that is propane-2,2-dithiol in which the hydrogens attached to both sulfur atoms are replaced by 3,5-di-tert-butyl-4-hydroxyphenyl groups. An anticholesteremic drug with antioxidant and anti-inflammatory properties, it is used to treat high levels of cholesterol in blood.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A total of 335 patients (206 men; mean age 72+/-9 years) with intermittent claudication were randomized according to a 2x2 factorial design to 1 of the 4 groups: probucol, placebo, EVBT, and EVBT+probucol." | 5.11 | Effects of probucol versus aspirin and versus brachytherapy on restenosis after femoropopliteal angioplasty: the PAB randomized multicenter trial. ( Alerci, M; Amann-Vesti, B; Aschwanden, M; Baumgartner, I; Bernier, J; Canevascini, R; Cozzi, L; Do, DD; Gallino, A; Greiner, R; Jacob, AL; Jäger, K; Kann, R; Kellner, F; Mahler, F; Schneider, E; Segatto, JM; Studer, G; Triller, J; Tutta, P, 2004) |
| "311 patients with STEMI were randomized to receive sirolimus- and probucol-eluting stents (n = 215) or zotarolimus-eluting stents (n = 96)." | 2.84 | Five-year follow-up of polymer-free sirolimus- and probucol-eluting stents versus new generation zotarolimus-eluting stents in patients presenting with st-elevation myocardial infarction. ( Byrne, RA; Cassese, S; Colleran, R; Giacoppo, D; Harada, Y; Ibrahim, T; Kastrati, A; Kufner, S; Lahmann, A; Laugwitz, KL; Lohaus, R; Repp, J; Schneider, S; Wiebe, J, 2017) |
| "In probucol-treated patients, the cross-sectional area (CSA) narrowing of 67." | 2.70 | Impact of residual plaque burden after balloon angioplasty in the MultiVitamins and Probucol (MVP) trial. ( Bilodeau , L; Côté , G; Couturier , A; de Guise , P; Doucet , S; Gallo , R; Gosselin , G; Grégoire , J; Harel , F; Joyal , M; Lespérance , J; Tardif , JC, 2001) |
| "Probucol (0." | 2.68 | Preventive effects of probucol on restenosis after percutaneous transluminal coronary angioplasty. ( Hashida, K; Ikeda, S; Miyagawa, M; Sekiya, M; Watanabe, K, 1996) |
| "Probucol (750 mg/day) was administered for at least 30 days prior to PTCA (34 patients, group P-1) or less than 14 days prior to PTCA (27 patients, group P-2)." | 2.68 | Effectiveness of probucol in preventing restenosis after percutaneous transluminal coronary angioplasty. ( Daida, H; Lee, YJ; Miyano, H; Mokuno, H; Sakurai, H; Takaya, J; Yamaguchi, H; Yokoi, H, 1996) |
| "Probucol was continued until follow-up angiography 24 weeks after PTCA." | 2.68 | Effectiveness of an antioxidant in preventing restenosis after percutaneous transluminal coronary angioplasty: the Probucol Angioplasty Restenosis Trial. ( Daida, H; Kanoh, T; Kato, K; Kutsumi, Y; Kuwabara, Y; Nakata, Y; Nishikawa, H; Nishimura, S; Nishiyama, S; Ohshima, S; Seki, A; Takatsu, F; Tomihara, H; Yamaguchi, H; Yokoi, H, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 14 (73.68) | 18.2507 |
| 2000's | 4 (21.05) | 29.6817 |
| 2010's | 1 (5.26) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Colleran, R | 1 |
| Kufner, S | 1 |
| Harada, Y | 1 |
| Giacoppo, D | 1 |
| Cassese, S | 1 |
| Repp, J | 1 |
| Wiebe, J | 1 |
| Lohaus, R | 1 |
| Lahmann, A | 1 |
| Schneider, S | 1 |
| Ibrahim, T | 1 |
| Laugwitz, KL | 1 |
| Kastrati, A | 1 |
| Byrne, RA | 1 |
| Gallino, A | 1 |
| Do, DD | 1 |
| Alerci, M | 1 |
| Baumgartner, I | 1 |
| Cozzi, L | 1 |
| Segatto, JM | 1 |
| Bernier, J | 1 |
| Tutta, P | 1 |
| Kellner, F | 1 |
| Triller, J | 1 |
| Schneider, E | 1 |
| Amann-Vesti, B | 1 |
| Studer, G | 1 |
| Jäger, K | 1 |
| Aschwanden, M | 1 |
| Canevascini, R | 1 |
| Jacob, AL | 1 |
| Kann, R | 1 |
| Greiner, R | 1 |
| Mahler, F | 1 |
| Kitazume, H | 1 |
| Ageishi, Y | 1 |
| Iwama, T | 1 |
| Kubo, I | 1 |
| Suzuki, A | 1 |
| Schneider, JE | 1 |
| Berk, BC | 1 |
| Gravanis, MB | 1 |
| Santoian, EC | 1 |
| Cipolla, GD | 1 |
| Tarazona, N | 1 |
| Lassegue, B | 1 |
| King, SB | 1 |
| O'Keefe, JH | 1 |
| Stone, GW | 1 |
| McCallister, BD | 2 |
| Maddex, C | 1 |
| Ligon, R | 1 |
| Kacich, RL | 1 |
| Kahn, J | 1 |
| Cavero, PG | 1 |
| Hartzler, GO | 1 |
| Watanabe, K | 2 |
| Sekiya, M | 2 |
| Ikeda, S | 1 |
| Miyagawa, M | 2 |
| Hashida, K | 1 |
| Lee, YJ | 1 |
| Daida, H | 2 |
| Yokoi, H | 2 |
| Miyano, H | 1 |
| Takaya, J | 1 |
| Sakurai, H | 1 |
| Mokuno, H | 1 |
| Yamaguchi, H | 2 |
| Tardif, JC | 2 |
| Cöté, G | 2 |
| Lespérance, J | 2 |
| Bourassa, M | 1 |
| Lambert, J | 1 |
| Doucet, S | 2 |
| Bilodeau, L | 2 |
| Nattel, S | 1 |
| de Guise, P | 1 |
| Libby, P | 1 |
| Ganz, P | 1 |
| Kuwabara, Y | 1 |
| Nishikawa, H | 1 |
| Takatsu, F | 1 |
| Tomihara, H | 1 |
| Nakata, Y | 1 |
| Kutsumi, Y | 1 |
| Ohshima, S | 1 |
| Nishiyama, S | 1 |
| Seki, A | 1 |
| Kato, K | 1 |
| Nishimura, S | 1 |
| Kanoh, T | 1 |
| Edelman, ER | 1 |
| Rodés, J | 1 |
| Bourassa, MG | 1 |
| Bertrand, OF | 1 |
| Harel, F | 1 |
| Gallo, R | 1 |
| Rashdan, I | 1 |
| Funada, J | 1 |
| Akutsu, H | 1 |
| Kanaki, T | 1 |
| Saito, Y | 1 |
| Merchán Herrera, A | 1 |
| López Mínguez, JR | 1 |
| Alonso Ruiz, F | 1 |
| Escola, JM | 1 |
| Címbora Ortega, A | 1 |
| Poblador Curto, MA | 1 |
| Redondo Méndez, A | 1 |
| Romero Santisteban, R | 1 |
| Geniz Gallardo, I | 1 |
| González Fernández, R | 1 |
| Millán Núñez, V | 1 |
| Titov, VN | 1 |
| Zaĭtseva, TM | 1 |
| von Hodenberg, E | 1 |
| Tost, B | 1 |
| Scheffold, T | 1 |
| Tardif , JC | 1 |
| Côté , G | 1 |
| Lespérance , J | 1 |
| Gosselin , G | 1 |
| Joyal , M | 1 |
| de Guise , P | 1 |
| Bilodeau , L | 1 |
| Doucet , S | 1 |
| Harel , F | 1 |
| Couturier , A | 1 |
| Gallo , R | 1 |
| Grégoire , J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Prospective, Randomized Trial of Rapamycin- and Zotarolimus-eluting Stents for the Reduction of Coronary Restenosis[NCT00598533] | Phase 4 | 3,002 participants (Actual) | Interventional | 2008-02-29 | Completed | ||
| Investigate Effect on Mean IMT of Probucol And/or CilosTazol in Patients With Coronary Heart dIsease Taking HMGCoA Reductase Inhibitor Therapy: A Randomized, Multicenter, Multinational Study[NCT01291641] | Phase 4 | 342 participants (Actual) | Interventional | 2011-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for probucol and Recrudescence
| Article | Year |
|---|---|
[Anti-atherogenic drugs].
Topics: Acute Disease; Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Bezafibrate; Coronary Disea | 1998 |
[Discrimination between the effects of hypolipidemic and antiatherogenic drugs: probucol pharmacokinetics (review of the literature)].
Topics: Angioplasty, Balloon; Angioplasty, Balloon, Coronary; Animals; Anticholesteremic Agents; Arterioscle | 2000 |
11 trials available for probucol and Recrudescence
| Article | Year |
|---|---|
Five-year follow-up of polymer-free sirolimus- and probucol-eluting stents versus new generation zotarolimus-eluting stents in patients presenting with st-elevation myocardial infarction.
Topics: Aged; Cardiovascular Agents; Coronary Thrombosis; Disease-Free Survival; Drug-Eluting Stents; Female | 2017 |
Effects of probucol versus aspirin and versus brachytherapy on restenosis after femoropopliteal angioplasty: the PAB randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Angioplasty, Balloon; Arterial Occlusive Diseases; As | 2004 |
[Ticlopidine may prevent subtotal or total occlusion of dilated lesions after percutaneous coronary angioplasty].
Topics: Angioplasty, Balloon, Coronary; Coronary Angiography; Coronary Disease; Drug Therapy, Combination; F | 1993 |
Lovastatin plus probucol for prevention of restenosis after percutaneous transluminal coronary angioplasty.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Constriction, Pathologic; Cor | 1996 |
Preventive effects of probucol on restenosis after percutaneous transluminal coronary angioplasty.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Cell Division; Cholesterol; C | 1996 |
Effectiveness of probucol in preventing restenosis after percutaneous transluminal coronary angioplasty.
Topics: Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Coronary Artery Disease; Female; Humans; M | 1996 |
Probucol and multivitamins in the prevention of restenosis after coronary angioplasty. Multivitamins and Probucol Study Group.
Topics: Angioplasty, Balloon, Coronary; Antioxidants; Ascorbic Acid; beta Carotene; Coronary Angiography; Co | 1997 |
Effectiveness of an antioxidant in preventing restenosis after percutaneous transluminal coronary angioplasty: the Probucol Angioplasty Restenosis Trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Antioxidants; Cholesterol; Combined | 1997 |
Prevention of restenosis after angioplasty in small coronary arteries with probucol.
Topics: Aged; Angioplasty, Balloon; Anticholesteremic Agents; Antioxidants; Coronary Angiography; Coronary D | 1998 |
Effects of probucol and cilostazol alone and in combination on frequency of poststenting restenosis.
Topics: Adult; Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Cilostazol; Coronary Angiography; C | 1998 |
Impact of residual plaque burden after balloon angioplasty in the MultiVitamins and Probucol (MVP) trial.
Topics: Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Antioxidants; Coronary Disease; Coronary V | 2001 |
6 other studies available for probucol and Recrudescence
| Article | Year |
|---|---|
Probucol decreases neointimal formation in a swine model of coronary artery balloon injury. A possible role for antioxidants in restenosis.
Topics: Animals; Antioxidants; Catheterization; Coronary Disease; Coronary Vessels; Female; Probucol; Recurr | 1993 |
Restenosis revisited--new targets, new therapies.
Topics: Angioplasty, Balloon, Coronary; Antioxidants; Coronary Disease; Drug Therapy, Combination; Humans; P | 1997 |
Vessel size, antioxidants, and restenosis: never too small, not too little, but often too late.
Topics: Angioplasty, Balloon; Anticholesteremic Agents; Antioxidants; Clinical Trials as Topic; Coronary Dis | 1998 |
Patient care after percutaneous coronary artery interventions.
Topics: Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Coronary Disease; Humans; Probucol; Recurr | 1998 |
[Reduction in the rates of restenosis after coronary angioplasty with simvastatin and probucol].
Topics: Aged; Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Cholesterol; Coronary Disease; Femal | 1999 |
[New strategies in the treatment of restenosis].
Topics: Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Anticholesteremic Agents; Athe | 2000 |